Pharmacokinetic Boosting of Osimertinib

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

October 31, 2021

Study Completion Date

December 31, 2021

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Cobicistat

Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).

Trial Locations (2)

6225EC

Maastricht University Medical Centre, Maastricht

1066CX

Antoni van Leeuwenhoek hospital, Amsterdam

All Listed Sponsors
collaborator

The Netherlands Cancer Institute

OTHER

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Academisch Ziekenhuis Maastricht

OTHER

NCT03858491 - Pharmacokinetic Boosting of Osimertinib | Biotech Hunter | Biotech Hunter